Ajanta Pharma Ltd (Ajanta Pharma) focuses on the development and commercialization of novel generic products. The business has a presence in cardiology, ophthalmology, dermatology, antimalarial, gastroenterology, antihistamine, respiratory and pain management. It offers anti-diabetics, anti-malarials, anti-biotics, beside drugs for cardiac, orthopedic, pediatric, gynec and respiratory conditions and general health.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Ajanta Pharma's R&D focuses on the advancement of novel products for addressing the evolving needs of patients, healthcare professionals, and society. The company focuses its R&D activities in the fields of cardiology, ophthalmology, dermatology, antimalarial, gastroenterology, antihistamine, respiratory and pain management. In FY2023, the company spent INR2552.1 million on its R&D activities, which as a percentage of revenue stood at 6.0%. It operates seven manufacturing facilities in Maharashtra, Gujrat, Assam, Madhya Pradesh and one R&D center for formulation development and API at Mumbai, India. In FY2023, the company has 21 pending approvals in ANDA and 46 ANDAs final ANDA approvals and three tentative approvals . The company has more than 850 scientists and two of their facilities are US FDA-approved.